QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group
19 Novembre 2024 - 10:54PM
Business Wire
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or
“QuidelOrtho”), a global provider of innovative in vitro
diagnostics technologies designed for point-of-care settings,
clinical labs and transfusion medicine, announced today the launch
of an underwritten secondary offering (the “Offering”) by Carlyle
Partners VI Cayman Holdings, L.P. (the “Selling Stockholder”) of
8,260,183 shares of the Company’s common stock (“Common
Stock”).
The Selling Stockholder will receive all of the proceeds from
the Offering. The Company is not selling any shares of Common Stock
in the Offering and will not receive any proceeds from the
Offering.
The last reported sale price of QuidelOrtho’s Common Stock on
November 19, 2024 was $38.58 per share. Goldman Sachs & Co. LLC
is acting as the sole underwriter of the Offering.
The underwriter proposes to offer the shares of Common Stock to
the public at a fixed price, which may be changed at any time
without notice.
Following the Offering, the Selling Stockholder will not
beneficially own any shares of QuidelOrtho’s Common Stock, other
than de minimis amounts held or owned from time to time in the
ordinary course of business. As a result, QuidelOrtho’s Principal
Stockholders Agreement with the Selling Stockholder will terminate
pursuant to its terms and the Selling Stockholder will no longer
have the right to nominate members to QuidelOrtho’s Board of
Directors in accordance with the terms of the Principal
Stockholders Agreement.
The Offering is being made pursuant to an effective shelf
registration statement (including a prospectus) filed by the
Company with the U.S. Securities and Exchange Commission (“SEC”) to
which this communication relates. Before you invest, you should
read the prospectus in the shelf registration statement and other
documents the Company has filed with the SEC for more complete
information about the Company and the Offering. The Offering will
be made only by means of a free writing prospectus, a prospectus
and a related prospectus supplement relating to the Offering,
copies of which may be obtained from Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, NY,
10282, phone number: (866) 471-2526, or by email at
prospectus-ny@ny.email.gs.com. A copy of the free writing
prospectus, the prospectus and the related prospectus supplement
relating to the Offering may also be obtained free of charge by
visiting EDGAR on the SEC’s website at www.sec.gov.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Cautionary Note Concerning Forward Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
These statements are any statement contained herein that is not
strictly historical, including, but not limited to, statements
regarding the expected sale of Common Stock by the Selling
Stockholder in the Offering. Without limiting the foregoing, the
words “may,” “will,” “would,” “should,” “might,” “expect,”
“anticipate,” “believe,” “estimate,” “plan,” “intend,” “goal,”
“project,” “strategy,” “future,” “continue” or similar words,
expressions or the negative of such terms or other comparable
terminology are intended to identify forward-looking statements.
Such statements are based on the beliefs and expectations of
QuidelOrtho’s management as of today and are subject to significant
known and unknown risks and uncertainties. Actual results or
outcomes may differ significantly from those set forth or implied
in the forward-looking statements. The factors discussed in
QuidelOrtho’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2023 and subsequent reports filed with the SEC,
including under Part I, Item 1A, “Risk Factors” of the Form 10-K,
among others, could cause actual results to differ from those set
forth or implied in the forward-looking statements. You should not
rely on forward-looking statements as predictions of future events
because these statements are based on assumptions that may not come
true and are speculative by their nature. All forward-looking
statements are based on information currently available to
QuidelOrtho and speak only as of the date hereof. QuidelOrtho
undertakes no obligation to update any of the forward-looking
information or time-sensitive information included in this press
release, whether as a result of new information, future events,
changed expectations or otherwise, except as required by law.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in
vitro diagnostics, developing and manufacturing intelligent
solutions that transform data into understanding and action for
more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular
testing, clinical chemistry, and transfusion medicine, bringing
fast, accurate and reliable diagnostics when and where they are
needed - from home to hospital, lab to clinic. So that patients,
clinicians and health officials can spot trends sooner, respond
quicker and chart the course ahead with accuracy and
confidence.
Building upon its many years of groundbreaking innovation,
QuidelOrtho continues to partner with customers across the
healthcare continuum and around the globe to forge a new diagnostic
frontier. One where insights and solutions know no bounds,
expertise seamlessly connects and a more informed path is
illuminated for each of us.
QuidelOrtho is advancing diagnostics to power a healthier
future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241112164377/en/
Investor Contact: Juliet Cunningham Vice President,
Investor Relations IR@QuidelOrtho.com Media Contact: D.
Nikki Wheeler Senior Director, Corporate Communications
media@QuidelOrtho.com
Grafico Azioni QuidelOrtho (NASDAQ:QDEL)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni QuidelOrtho (NASDAQ:QDEL)
Storico
Da Dic 2023 a Dic 2024